The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Press Releases Subscribe to our News

25. Mai 2022

Non-Regulatory

NOTICE OF ANNUAL GENERAL MEETING IN BIOSERGEN AB

Release

Non-Regulatory

KALLELSE TILL ÅRSSTÄMMA I BIOSERGEN AB

Release
02. Mai 2022

Non-Regulatory

Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.

Release
19. April 2022

Non-Regulatory

The first subjects dosed successfully with no adverse events in the phase I trial of BSG005

Release
24. August 2021

Non-Regulatory

Biosergen’s application to start human clinical trials with BSG005 is approved

Release
19. August 2021

Non-Regulatory

Tine Kold Olesen will join Biosergen AB as Chief Operating Officer

Release
23. Juni 2021

Non-Regulatory

BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.

Biosergen listing approval
31. Mai 2021

Non-Regulatory

The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity

Release
19. Mai 2021

Non-Regulatory

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)

Non-Regulatory

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)